68 citations
,
April 2014 in “Journal of Molecular Endocrinology” The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
1 citations
,
September 2020 in “Endocrinology, Diabetes & Metabolism Case Reports” The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.
March 2010 in “Ejc Supplements” ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
January 2017 in “Journal of Antivirals & Antiretrovirals” Treatment strategies for breast cancer affect blood health, causing issues like anemia and require nutritional counseling.
21 citations
,
March 2019 in “Critical Reviews in Clinical Laboratory Sciences” The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
2 citations
,
May 2012 in “Annals of Oncology” Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.
6 citations
,
January 2010 in “Neoplasma” Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.
67 citations
,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
February 2024 in “PloS one” Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.
8 citations
,
June 2022 in “Cancers” Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.
1 citations
,
July 2021 in “Frontiers in Oncology” Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.
8 citations
,
July 2022 in “International Journal of Molecular Sciences” 17β-estradiol lowers polyamine oxidase levels in breast cancer cells through estrogen receptor 2.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” Hair growth supplements do not reduce the effectiveness of the breast cancer treatment tamoxifen.
6 citations
,
September 2024 in “Current Oncology” Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
June 2023 in “Journal of multidisciplinary sciences (Online)” PCOS is linked to a higher risk of endometrial cancer but not ovarian or breast cancer, and more research is needed on its role in cancer development and treatment effects.
March 2010 in “Ejc Supplements” CK 5/6 expression in breast cancer is linked to negative hormone receptor status and higher tumor grade.
February 2022 in “Research Square (Research Square)” Certain nutraceuticals may enhance hair growth without affecting the cancer-fighting properties of tamoxifen.
December 2021 in “Research Square (Research Square)” Hair growth-promoting nutraceuticals do not block the cancer-fighting effects of tamoxifen and may enhance its action.
7 citations
,
September 2023 in “Cancer Treatment Reviews” Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.
7 citations
,
September 2024 in “Journal of Comparative Effectiveness Research” Palbociclib generally maintains or improves quality of life in advanced breast cancer patients.
October 2025 in “Journal of the Endocrine Society” Anastrozole can cause increased testosterone, leading to symptoms like hair growth and thinning.
The conclusion is that endocrinology significantly impacts medicine with various common medications used for treatment.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
4 citations
,
October 2018 in “International Braz J Urol” Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.
6 citations
,
November 2021 in “Oncology Research and Treatment” Low Vitamin D receptor levels in breast cancer are linked to worse outcomes and more bone metastases, and could be a marker for prognosis.
4 citations
,
November 2022 in “BMC Women s Health” HER2-targeted or hormonal therapies improve quality of life for Sudanese breast cancer patients.